Company Overview
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with PD; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; SLS-004 for the treatment of PD; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. Seelos Therapeutics, Inc. was incorporated in 1987 and is headquartered in New York, New York.
Company Information
- CEO
- Raj Mehra
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 8
Contact Information
- Address
- 300 Park Avenue
- Country
- US
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 214.97K market capitalization
- Trading Volume: 0 shares traded today
- Price Range: 52-week range of $0.37 - $0.37
- Exchange: Listed on NASDAQ Capital Market
Financial Metrics
Market Analysis for Seelos Therapeutics, Inc.
Seelos Therapeutics, Inc. (SEEL) operates in the Biotechnology industry within the Healthcare sector. With a current market capitalization of 214.97K, the company represents a significant player in its market. The stock is currently trading at $0.37 with a positivedaily change of 0.00%.
The company's 8 employee base and presence on the NASDAQ Capital Marketexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of 0.00, beta of 1.94, and 52-week price range from $0.37 to $0.37when evaluating investment opportunities.
Why Invest in Seelos Therapeutics, Inc.?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (NASDAQ Capital Market)
- • Experienced leadership under Raj Mehra
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.